Lilly announces three acquisitions to build infectious disease portfolio | Eli Lilly and Company - investor.lilly.com
Consumer
Eli Lilly announced three acquisitions targeting infectious disease/vaccines for up to ~$3.8B, signaling a strategic pivot beyond its dominant GLP-1 franchise. This diversification move is classic late-cycle portfolio-building but raises capital-allocation questions at a time when the market is already debating GLP-1 growth durability.
0 reads·0 theses
Angle
↓ SHORT-5% target+3% stop2-3 weeks
Fade the initial pop in LLY — $3.8B in vaccine bolt-ons signals GLP-1 confidence is softening and consensus already reflects the bull case at 19 Buys with 2 recent insider sells.